VANCOUVER, June 25, 2019 /CNW/ - PRESS RELEASE - C21 Investments, Inc. has announced that it has created a wholesale distribution company, C21 Supply Co. The supply company will further unify and accelerate B2B efforts with C21's consumer packaged goods (CPG) brands: Phantom Farms, Dab Society, Hood Oil and Eco Firma Farms in Oregon and, in due course, Nevada. C21 Supply Co. will distribute a wide selection of THC and CBD products, including cannabis flower, pre-rolls and cannabis oil extracts.

"C21 Supply Co. is a key part of our vertical integration model that will provide a one-stop shop for dispensaries who want to distribute our highly respected CPG brands," said Robert Cheney, president and CEO of the company. "C21 Supply Co. will be a single point of contact for efficient order processing and invoicing, making merchandising easier and more accessible for our wholesale partners."

The C21 Supply Co. mission is simple: provide unrivaled quality, professionalism, service and partnership to like-minded companies in the cannabis industry.

DENVER, June 24, 2019 /PRNewswire/ -- PRESS RELEASE -- Helix TCS, Inc. technology subsidiary, BioTrackTHC, has been awarded a contract by the New Hampshire Department of Health and Human Services (DHHS) to provide its Therapeutic Cannabis Program (TCP) Patient Registry System to electronically process and track patient and caregiver card applications. The company has a separate contract with all of the New Hampshire Alternative Treatment Centers (ATC), referred to as "dispensaries" in most states, for seed to sale inventory tracking. The contract's life is through December 31, 2021, and is valued at $400,000. With the addition of this contract, BioTrackTHC provides government cannabis regulatory technology to 10 U.S. states and territories, and was recently awarded seed to sale traceability contract extensions in Illinois, Hawaii and Delaware.

"Our platform of critical infrastructure services has a proven track record in creating streamlined, transparent, and secure cannabis programs as we have demonstrated by empowering some of the soundest programs in the country," said Moe Afaneh, COO of BioTrackTHC. "We look forward to providing New Hampshire with the same level of industry-leading technology, service and peace of mind that has made our other contract partners so successful."

"As the legal cannabis industry expands into new markets and the global industry matures, technology that facilitates transparency and product quality are essential to ensuring safety among the communities and longevity of the industry," said Zachary L. Venegas, executive chairman and CEO of Helix TCS, Inc. "We have proven our ability to empower safe and accountable cannabis programs and look forward to seeing more states start down the path of legal cannabis."

BALTIMORE, MD. — PRESS RELEASE — The University of Maryland School of Pharmacy has launched a new Master of Science (MS) in Medical Cannabis Science and Therapeutics to provide students with the knowledge and skills needed to support patients and the medical cannabis industry, add to existing research in the field, and develop well-informed medical cannabis policy. Based at the Universities at Shady Grove (USG) in Rockville, Md., the two-year program blends online learning with face-to-face experiences, and is designed for any individuals who has  completed his or her undergraduate degree and is interested in pursuing a career in the medical cannabis industry.

The MS in Medical Cannabis Science and Therapeutics is the first graduate program in the country dedicated to the study of medical cannabis. It aims to meet the needs of all individuals interested in advancing their knowledge about medical cannabis, including health care professionals such as physicians, nurses, and pharmacists; scientists and regulators; growers and dispensary owners; and policy and industry professionals.

“Medical cannabis has been legalized in 33 states, including Maryland, as well as in Washington, D.C., Guam, and Puerto Rico,” says Natalie D. Eddington, PhD, FCP, FAAPS, dean and professor of the School of Pharmacy. “This number is only expected to increase in the future, fueling a demand for an educated workforce that is well-trained in both the science and therapeutic effects associated with this medicinal plant. Our MS in Medical Cannabis Science and Therapeutics has been critically designed to prepare students to meet this demand. Innovations in instructional design throughout the curriculum will provide students with the knowledge and skills needed to make a positive impact on communities across the United States.”

The School of Pharmacy’s MS in Medical Cannabis Science and Therapeutics addresses the areas of basic science, clinical use, adverse effects and public health, and federal and state laws and policies surrounding medical cannabis. Online coursework is designed to accommodate students with or without a background in science or medicine, as well as offer flexibility when completing assignments. In-person symposia held once each semester at USG provide students with opportunities to network with peers, as well as meet and interact with experts in the science, therapeutics, and policy of medical cannabis.

The application deadline for this program is August 15, for classes beginning on August 26, 2019.

“The MS in Medical Cannabis Science and Therapeutics is an incredibly unique program,” says Leah Sera, PharmD, MA, BCPS, assistant professor in the Department of Pharmacy Practice and Science at UMSOP, director of the MS in Medical Cannabis Science and Therapeutics program, and a clinical pharmacist who practices in the field of palliative care. “Faculty from the School of Pharmacy who lead courses for the program are experts in both basic and clinical sciences related to the study of medications, and are dedicated to making coursework both interesting and accessible to all students.”

She adds, “There is truly no other educational program that offers the in-depth instruction on the science, policy, and therapeutics of medical cannabis that students who are accepted into our program will receive.”

To better meet the needs of working professionals, the MS in Medical Cannabis Science and Therapeutics does not require the completion of a thesis. Instead, students complete a capstone course that features a selection of expert seminars, case studies and discussions. Graduates of the program will be able to help identify patients appropriate for medical cannabis therapy and determine appropriate dosing and administration for those patients; ensure the safe and effective design, development, and manufacture of medical cannabis products; identify potential research opportunities related to the science and health effects of the cannabinoids found in medical cannabis; and participate in health policy decision-making processes related to medical cannabis.

“Students who complete our program will have an unparalleled competitive advantage when it comes to pursuing or advancing a career in the medical cannabis industry,” says Sera. “These individuals will be well-prepared to support patients and the medical cannabis industry with the knowledge and skills gained from their coursework. They will also be able to add to existing clinical and scientific research on medical cannabis, and will be able to contribute to well-informed policies related to medical cannabis.”

The MS in Medical Cannabis Science and Therapeutics welcomes students who possess a bachelor’s degree from an accredited college or university, currently work or are interested in working in the medical cannabis industry, and have the ability to travel once per semester to attend required symposia at USG, which is located in a suburb of the nation’s capital.

ATLANTA, Georgia – June 21, 2019 – PRESS RELEASE – Surterra Wellness, a health and wellness company, has announced the close of its acquisition of Massachusetts-based New England Treatment Access (NETA), a vertically integrated cannabis company.

The Commonwealth of Massachusetts is one of the fastest growing medical and adult cannabis markets in the U.S. This is Surterra’s second acquisition in six months, and reflects Surterra’s approach of bringing operational cannabis companies with established brands, comparable values and industry-leading standards under the Surterra umbrella. The deal adds a fourth U.S. cannabis market and another revenue-generating vertical operation to Surterra’s rapidly expanding national footprint, which also includes operations Florida, Nevada and Texas.  The combined company will have more than 1,500 employees.

“This is a synergistic partnership. NETA’s foundational values and reputable track record align with Surterra’s own vision for long-term success in this rapidly evolving cannabis industry. We welcome the talented NETA leadership team and their proven operations and product development expertise. Their experience will accelerate Surterra’s ability to quickly and strategically scale as we become a global frontrunner in this space,” said Surterra Chief Executive Officer William “Beau” Wrigley, Jr. “Surterra will immediately integrate NETA’s best practices in patient and customer service, research and development, product production, compliance and year-round indoor grow capabilities across our company’s operations.  We thank the Cannabis Control Commission for its approval of the acquisition and the communities of Brookline, Franklin and Northampton for all of their support.”

NETA co-founder Kevin Fisher joins Surterra’s leadership team as executive director of operations, effective immediately. An industry pioneer in regulated medical and adult-use cannabis, Fisher has owned and operated facilities in Colorado and Massachusetts under the Rocky Mountain Remedies and NETA brands since 2009. Fisher also co-founded and served as the CEO of Molecular Infusions (Mi), a world class, cannabinoid-focused, biopharmaceutical company based in Boston.

“NETA’s leadership and talented employees are thrilled to join Surterra. Together, we can build upon what NETA has already accomplished in ways that bring superior products and services to our current, and future, patients and customers. Like us, Surterra seeks meaningful collaborations with best-in-class, like-minded partners. They understand the long-term value of building brands and operational capabilities needed to execute on a large scale,” said Fisher.  “NETA will continue to provide patients and customers in the Commonwealth of Massachusetts with the high-quality brands and extraordinary service that they have come to expect.  Additionally, our focus on the deployment of strong diversity programs and strategic community partnerships will go forward unabated.”

Terms of the Deal

The financial terms of the cash and stock transaction are undisclosed. Surterra’s acquisition of NETA positions the combined business as a global cannabis sector leader in revenue and earnings. The deal includes Surterra’s full acquisition of NETA’s indoor grow, processing, R&D, product development and retail operations, as well as all medical and adult-use brands marketed through NETA facilities, including all associated intellectual property. NETA currently operates retail dispensaries in Brookline and Northampton, and cultivation and processing facilities in Franklin. The NETA team has built a world class, 100,000-square-foot indoor facility that houses cultivation, extraction and infusion technologies. The company offers a portfolio of more than 250 SKUs, covering a wide range of cannabis products and a large variety of strains.